

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 92697

Title: Efficacy and safety of Yangxinshi tablet for chronic heart failure: A systematic review and meta-analysis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04159375

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Attending Doctor, Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2024-02-02

Reviewer chosen by: AI Technique

Reviewer accepted review: 2024-02-06 06:19

Reviewer performed review: 2024-02-08 12:10

Review time: 2 Days and 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This reviewer think that the theme of this article is interesting, but popular in the area other than China globally. In this regards, this paper is valuable. However, this reviewer would like to give some comments on this paper. Major concerns: 1. Fist of all, the world journal of gastroenterology is not suitable to this article. The world journal of cardiology would be suitable for target readers, because the novel treatment such as Yangxinshi Tablet for chronic cardiac failure is being explored in the world. 2. Please add the information about left ventricular function and type of chronic heart failure (HFrEF/HFpEF etc.) and baseline cardiac disease (ischemic/non ischemic) in each adopted study in Table 1. By this information readers will be able to know which patients were treated with Yangxinshi Tablet in the review and met-analysis. 3. To know the effects of Yangxinshi Tablet on cardiac failure, it would be crucial to consider the use the guidelines-based treatment (β blocker, ACEI/ARB, MRA, SGLT2i, ARNI etc.) in all patients. Please show the prescription rate and adherence to the guidelines-based treatments in the adopted studies. 4. The treatment strategy for HFrEF has been almost established. Meanwhile, the beneficial drugs for HFpEF is scarce besides SGLT2i and



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

ARNI. Thus, readers may want to know the effects of Yangxinshi Tablet on HFpEF. Please show the data and or discuss about this theme. 5. In Page 11 Lines 1-3 Left ventricular diastolic function can not be evaluated by LVEDD, LVESD, or LVEF. Thus, this description is incorrect. Minor concerns: 1. Page 4: Line 3 from the bottom: TCM Please show the full spelling at the first presentation for TCM. 2. Page 4 Line 3 from the bottom to Page 5 Line 5 Please add the references for this sentence. 3. Please add the Chinese name in Chinese letters for Yangxinshi Tablet, Qi, Yang. 4. Page 6 the boeeom line In each exercise→Please explain these words. I cannot understand them. 5. Reference 「20」 Is the data incomplete? 6. Please explain the missing data in male age in Table 1.